



September 03, 2021

To  
**National Stock Exchange of India Limited,**  
Compliance Department,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051,  
Maharashtra, India

To  
**BSE Limited,**  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001,  
Maharashtra, India

Dear Sir/Madam,

**Subject:** **Intimation regarding execution of Business Transfer Agreement (“BTA”) and Share Purchase Agreement (“SPA”) by HealthCare Global Enterprises Limited (“the Company” or “HCG”).**

**Reference:** **Regulation 30 (3) and (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Scrip Code:** **NSE Scrip Code: HCG; BSE Scrip Code: 539787**

The Company has divested its entire equity holding of 34.5% (on a fully diluted basis) of the share capital in Strand Life Sciences Private Limited (“**Strand**”) an associate of the Company to Reliance Strategic Business Ventures Limited (“**RSBVL**”) pursuant to a Share Purchase Agreement executed by the Company on September 03, 2021 (“**SPA**”) for a cash consideration of INR 157,77,57,968 (Indian Rupees One Hundred Fifty-Seven Crore, Seventy-Seven Lakh, Fifty-Seven Thousand, Nine Hundred and Sixty-Eight Only).

Apart from the SPA, the Company has also entered into Business Transfer Arrangement with Strand on September 03, 2021 (“**BTA**”) of the Hospital Lab Management (HLM) and Clinical Research Site Management (SMO) units back to HCG from Strand Life Sciences for a gross cash consideration of INR 80,80,00,000 (Indian Rupees Eighty Crores, Eighty Lakhs Only).

**Additional Disclosures as required under SEBI Circular No. CIR/CFD/CMD/4/2015, dated September 09, 2015:**

### **1. Share Purchase Agreement**

*a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;*

Strand Life Sciences is an associate of the Company and its financial statements are not consolidated with the financial statements of the Company. Hence the turnover or net worth of Strand Life Sciences is not a part of the turnover or net worth of the Company.

**HealthCare Global Enterprises Limited**

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



b) *Date on which the agreement for sale has been entered into;*

The Company has executed the SPA on September 03, 2021.

c) *The expected date of completion of sale/disposal;*

The sale/disposal of the shares owned by the Company in Strand Life Sciences is expected to be completed on September 06, 2021.

d) *Consideration received from such sale/disposal;*

The Company has received INR 157,77,57,968 (Indian Rupees One Hundred Fifty-Seven Crore, Seventy-Seven Lakh, Fifty-Seven Thousand, Nine Hundred and Sixty-Eight Only) representing 34.5% of the share capital on fully diluted basis of Strand Life Sciences.

e) *Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;*

The buyer is Reliance Strategic Business Ventures Limited, a limited company duly incorporated under the laws of India, bearing corporate identification number U74999GJ2019PLC108789, and having its registered office at Office-101, Saffron, Nr Centre Point Panchwati 5 Rasta, Ambawadi, Ahmedabad – 380006. The buyer does not belong to the promoter/promoter group/group companies of the Company.

f) *Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;*

The transaction would not fall within the purview of related party transaction.

g) *Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale. (For the purpose of this sub-clause, "slump sale" shall mean the transfer of one or more undertakings, as a result of the sale for a lump sum consideration, without values being assigned to the individual assets and liabilities in such sales.)*

Not Applicable

## **2. Business Transfer Agreement:**

(a) *Name of the target entity, details in brief such as size, turnover, etc.;*

The name of the target entity is Strand Life Sciences Private Limited (Strand or Strand Life Sciences).



The Company (HCG), through the BTA is acquiring only erstwhile HCG's the Hospital Lab Management (HLM) and Clinical Research Site Management (SMO) units of Strand Life Sciences. Hence the details in terms of size and turnover of the entity is not being provided.

Strand Life Sciences is engaged in the business of developing, implementing and deploying technology for data, image and text analysis, and for diagnostic testing in the fields of genomics, research, pharmaceutical research and development, biotechnology and healthcare.

*(b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";*

The acquisition would fall within the meaning of 'related party transaction', as Strand Life Sciences is an associate of the Company and have common directors. The transaction under the BTA is at arm's length.

*(c) Industry to which the entity being acquired belongs;*

Strand Life Sciences belongs to healthcare industry.

*(d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);*

The transactions are part of the Company's initiative to focus on integrated end-to-end Oncology scale-up.

The target entity operates in the same industry in which the Company also operates.

*(e) Brief details of any governmental or regulatory approvals required for the acquisition;*

No governmental or regulatory approvals are required for this acquisition.

*(f) Indicative time period for completion of the acquisition;*

The consummation of transaction under the BTA is expected to be completed on or before September 10, 2021 or such later date agreed among the parties in writing.

*(g) Nature of consideration - whether cash consideration or share swap and details of the same;*

The consideration for the acquisition of the Business Undertaking by the Company, is in the form of cash.



*(h) cost of acquisition or the price at which the shares are acquired;*

The gross cash consideration for the purchase of the Business Undertaking of Strand Life Sciences is INR 80,80,00,000 (Indian Rupees Eighty Crores, Eighty Lakhs Only).

*(i) percentage of shareholding / control acquired and / or number of shares acquired;*

The Company is acquiring the Business Undertaking of Strand Life Sciences as per the BTA. No acquisition of shareholding/control is contemplated through this arrangement.

*(j) brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, country in which the acquired entity has presence and any other significant information (in brief);*

Strand Life Sciences is engaged in the business of developing, implementing and deploying technology for data, image and text analysis, and for diagnostic testing in the fields of genomics, research, pharmaceutical research and development, biotechnology and healthcare.


Strand Life Sciences was incorporated on October 06, 2000, in the State of Karnataka and the registered office is at University of Agricultural Sciences, Convention - Centre Veterinary College Campus, Bellary Road, Bengaluru, Karnataka 560 024.

On completion of the sale/transfer of entire shareholding of the Company in Strand Life Sciences, the Company would cease to be a shareholder of Strand Life Sciences; and accordingly, Strand Life Sciences would cease to be an associate of the Company.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

**For HealthCare Global Enterprises Limited**



**Sunu Manuel**  
**Company Secretary & Compliance Officer**